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Lack of expression of the chondroitin sulphate proteoglycan
neuron-glial antigen 2 on candidate stem cell populations in
paediatric acute myeloid leukaemia/abn(11q23) and acute
lymphoblastic leukaemia/t(4;11)
Increasing evidence suggests that, similar to normal haemato-
poiesis, acute leukaemic patients are maintained by a small
subpopulation of highly specialised malignant stem cells
(McCulloch, 1983; Griffin & Lo¨wenberg, 1986; Lapidot et al,
1994; Bonnet & Dick, 1997). Differences between normal and
leukaemic stem cells with regard to survival pathways,
proliferation signals, regulation of apoptosis and interaction
with the bone marrow microenvironment constitute potential
therapeutic targets. Due to the similarities between normal and
leukaemic haematopoietic stem cells, it has been impossible to
purify leukaemic stem cells to high purity. Purification of
leukaemic stem cells is, however, a prerequisite for studying
their biology and to understand the differences between
normal and leukaemic stem cells. Thus, it is of the utmost
importance to identify markers specific for leukaemic stem
cells.
First described on rat oligodendrocyte progenitor cells
(Stallcup & Cohn, 1976), the chondroitin sulphate proteogly-
can neuron-glial antigen 2 (NG2) molecule and its human
homologue is known to be expressed in the vascular system,
skeletal and cardial myoblasts, chondroblasts and different
human tumours as well. Its physiological function has still not
been completely understood, but recent evidence indicates that
NG2 is involved in signalling pathways that regulate the
proliferation and migration of precursor cells (Levine &
Nishiyama, 1996). While NG2 cannot be detected on the
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Summary
It has increasingly been acknowledged that only a few leukaemic cells possess
the capability to renew themselves and that only these self-renewing
leukaemic stem cells are able to initiate relapses. Therefore, these leukaemic
stem cells should be the target cells for therapy and for minimal residual
disease (MRD) detection. Because of its presence on blasts of 11q23-
rearranged high-risk leukaemic patients, neuron-glial antigen 2 (NG2) is
thought to be a valuable marker for detecting leukaemic stem cells. Six acute
myeloid leukaemia (AML)/abn(11q23) and three acute lymphoblastic
leukaemia (ALL)/t(4;11) samples were analysed by four-colour flow
cytometry for NG2 expression on primitive cell populations. Candidate
leukaemic cell populations were defined by the antigen profiles CD34+CD38)
in AML and CD34+CD19)CD117+ in ALL. Surprisingly, in all patients these
candidate stem cell populations were shown to lack expression of NG2.
Instead, a correlation between the expression of the myeloid differentiation
marker CD33 and increasing levels of NG2 on maturing cells could be
demonstrated. Similarly, in ALL patients CD34+CD19+ cells showed a higher
expression of NG2 mRNA compared with CD34+CD19). Thus, NG2 appears
to be upregulated with differentiation and not to be expressed on primitive
disease-maintaining cells. This hampers the clinical use of NG2 as a
therapeutic target and as a sensitive marker for MRD detection.
Keywords: leukaemic stem cell, neuron-glial antigen 2, 11q23, acute
lymphoblastic leukaemia, acute myeloid leukaemia.
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surface of normal haematopoietic precursor cells, the mono-
clonal antibody 7Æ1 (moAb 7Æ1) recognises the 220–240 kDa
chondroitin sulphate proteoglycan NG2 on 11q23/mixed
lineage leukaemia (MLL)-rearranged leukaemic blasts (Smith
et al, 1996). Although NG2 seems to promote the metastatic
potential of melanoma cells (Burg et al, 1998), a biological
function of NG2 in leukaemic patients with 11q23/MLL
rearrangements has yet to be identified.
Throughout the past years, NG2 has been incorporated in
diagnostic panels for immunophenotyping of leukaemic
patients because of its positive predictive value for MLL
rearrangements in childhood and adult acute myeloid leukae-
mia (AML) and acute lymphoblastic leukaemia (ALL). In
addition, NG2 expression has been evaluated concerning the
detection of persisting minimal residual disease (MRD) (Behm
et al, 1996; Smith et al, 1996; Hilden et al, 1997; Wuchter et al,
2000; Borkhardt et al, 2002; Schwartz et al, 2003).
Based on the specificity of NG2 expression on haematopoi-
etic cells for 11q23/MLL-rearranged leukaemic patients, we
report here our efforts to evaluate NG2 expression as a marker
for leukaemic stem cells.
Materials and methods
Patients and cell samples
We examined bone marrow or peripheral blood samples from
11 paediatric patients [eight AML: unique patient numbers
(UPNs) 01–08; 3 ALL: UPN 1–2, 10] with 11q23/MLL gene
rearranged leukaemia by flow cytometry. Two of the 11 patients
(UPN 07, 08) were excluded, because they tested negative for
NG2. Of the remaining nine patients, two patients were treated
at the Department of Paediatric Haematology and Oncology,
University of Mu¨nster. Six samples were provided by the
Berlin-Frankfurt-Mu¨nster AML (AML-BFM) MRD study
group, and one by the Erasmus MC-Sophia Children’s
Hospital. All samples were obtained at the time of diagnosis
after informed consent from the guardians and stored in liquid
nitrogen. The ethics committee of the Medical Faculty,
University of Mu¨nster, approved the investigation. Four of
six AML patients were positive for the translocation
t(9;11)(p22;p23), one had a translocation t(10;11). In one
patient the MLL translocation partner could not be identified
(t(?;11)), but an 11q23 rearrangement was revealed by fluor-
escence in situ hybridisation (FISH). All ALL patients had a
translocation t(4;11) in the leukaemic clone. Two of the ALL
samples (UPN 1, 2) were also available for RNA-based analyses.
From additional four ALL/t(4;11) samples, only RNA
samples for molecular analysis were available (provided by
the ALL-BFM study group) (UPN 3–5, 9). The ALL patient
numbers match the UPN used by Hotfilder et al (2005) and
are identical samples.
Cell lines HeLa, K562 and MV4;11 were used as negative
and positive controls, respectively, for the subsequent
investigations.
Flow cytometry
The AML samples were stained at saturating concentrations
with: anti-NG2 (moAb 7Æ1) – phycoerythrin (PE), anti-CD34-
allophycocyanin (APC), anti-CD33-PE-cyanin-5Æ1 (PECy5)
and anti-CD38-fluorescein isothiocyanate (FITC) antibodies.
The ALL samples were stained with the following antibody
panel: anti-NG2-PE, anti-CD34-APC, anti-CD19-FITC and
anti-CD117-PECy5 (isotype control for all antibodies: mouse
immunoglobulin (Ig)G1; all antibodies from Immunotech,
Beckman Coulter, Marseille, France). In each patient,
5 · 106 cells were incubated with the specific antibody panel
and another 5 · 106 cells were incubated with mouse IgG
isotype-control antibodies. After having been stained with the
antibodies at room temperature for 20 min, the samples were
incubated with BD lysis for 5 min. Subsequently, the samples
were washed twice with phosphate-buffered saline (PBS),
centrifuged at 260 g, 5 min, 21C, and resuspended in PBS.
Time delay calibration was accomplished prior to each
measurement using APC beads following the manufacturer’s
instructions. Calibration and compensation were achieved by
analysing unstained and single-stained anti-CD38-FITC, anti-
CD33-APC, anti-CD33-PE and anti-CD33-PECy5 of AML and
single-stained anti-CD19-PE, anti-CD19-FITC, anti-CD19-
APC and anti-CD19-PECy5 cells of ALL samples.
Flow cytometry measurements were performed according to
the published protocols (Vormoor et al, 1998; Baersch et al,
1999). Detection of NG2 and immunophenotypic analyses
were carried out on a FACSCalibur, by using the cell quest
pro and paint-a-gate software [Becton Dickinson (BD),
Heidelberg, Germany]. After calibration and compensation as
described above, 10 000 events were acquired of both the
specific- and the isotype-stained cells. Subsequently, a storage
gate was set on the CD34+CD38) events for AML or on the
CD34+CD19) events for ALL samples. Another 1 · 106 cells
(ALL patient no. 10: 6 · 105 cells) of the same samples were
acquired and only the gated events were stored. Between the
single runs, the FACSCalibur was flushed with FACSRinse
(BD) and distilled water, in order to avoid a carryover of cells
from previous runs. The next run was not started until the
number of events within the pure water-run was below 15
events in 1:30 min. In general, the acquisition speed was kept
between 1000 and 2000 events/min.
Sorting of cells for reverse-transcriptase polymerase chain
reaction analysis and isolation of RNA
Sorting and RNA-isolation strategies have previously been
described (Hotfilder et al, 2002). From each population
(CD34+CD19) and CD34+CD19+) a total of 1000 cells were
sorted directly into 100 ll of RLT buffer (supplied with the
RNeasy-Mini-Kit; Qiagen, Hilden, Germany); after 250 ll of
RLT buffer and 3Æ5 ll of b-mercaptoethanol were added, the
samples were passed through Qiashredder columns (Qiagen)
according to the manufacturer’s protocol. The lysate was
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frozen and stored at )80C. According to the RNeasy-Mini-Kit
(Qiagen) protocol, total RNA was extracted from frozen lysate.
RNA was finally eluted with 30 ll of ribonuclease-free water
and stored at )80C.
Reverse-transcriptase polymerase chain reaction for NG2
RNA-based methods were carried out by using a nested reverse-
transcriptase polymerase chain reaction (RT-PCR). For the first
amplification round, the OneStep RT-PCR kit (Qiagen) was
used. Five microlitres of total RNA was transcribed into
complementary DNA and amplified. The reaction solution had
a total volume of 50 ll containing 0Æ2 lmol/l of each primer
(sense: GAACTTCACTCAGGCAGAGGTC, antisense: CTGTG
TGACCTGGAAGAGCA), 400 lmol/l of each deoxyribonucle-
oside triphosphate, 1x OneStep RT-buffer, and OneStep RT-
PCR enzyme mix. The RT reaction and amplification condi-
tions were 30 min at 50C, 15 min at 95C, followed by 35 PCR
cycles (30 s at 94C, 30 s at 55C, 45 s at 72C), terminated by
an extension step of 10 min at 72C and a final cooling down to
12C. A total of 20 ll of each PCR reaction mixture was applied
to 0Æ8% agarose gel stained with 0Æ5 lg/ml ethidium bromide
and visualised under ultraviolet illumination. Finally, the
expected and obtained 345-bp PCR products were isolated
and sequenced in order to check the identity of the obtained
amplification products (Cycle SeqKit; Applied Biosystems,
Weiterstadt, Germany).
For semiquantification the second PCR was performed on
the LightCycler instrument by using the LightCycler-DNA-
master-SYBR-green-I-kit (Roche, Mannheim, Germany). In
accordance with the manufacturer’s protocol the hot-start
method was used (Taq-Start antibody; Clontech, Heidelberg,
Germany). The second PCR reaction mix contained 2 ll
amplification product of the first PCR, 0Æ2 lmol/l of each
second nested primer (sense: AGAGACCTTTGTTCTTCCA-
GAGG, antisense: GGTCTACGCTGGGAATATTCTGT),
3 mmol/l of MgCl2 and 1x LightCycler-DNA-master-SYBR-
green buffer. Cycling conditions were set to 2 min at 95C,
followed by 40 PCR cycles (1 s at 94C, 5 s at 55C, 10 s at
72C). A standard curve was generated by RT-PCR analysis
with dilutions of 10, 10)1, 10)2 and 10)3 of RNA from the
NG2-positive cell line HeLa and a semilogarithmic regression
curve for relative quantification was calculated (regression
curve equation: x ¼ e2Æ424)0Æ35y, where x is relative NG2 RNA
concentration and y is obtained crossing point).
Results
NG2 expression of the bulk leukaemic population
In order to determine NG2 cell surface expression, diagnostic
bone marrow or peripheral blood samples from 11 paediatric
patients with MLL gene-rearranged acute leukaemia were
analysed by flow cytometry (Figs 1A and 2A). The blasts of
six AML and three ALL samples were positive for NG2 and
constituted the sample collective of the following investiga-
tions.
Determination of NG2 expression on primitive leukaemic
progenitor cell populations
In the next step, NG2 expression on immature CD34+ cell
populations was analysed. Immature, non-lineage committed
progenitor/stem cells were defined by a CD34+CD38) (in AML
samples) or a CD34+CD19) immunophenotype (in ALL
samples).
The leukaemic stem cell population in AML has been shown
to be CD34+CD38) (Lapidot et al, 1994; Bonnet & Dick, 1997;
Blair et al, 1998; Bonnet, 2005). Cells with this CD34+CD38)
immunophenotype are rare in diagnostic bone marrow and
peripheral blood samples, and the percentage varied between
0Æ02 % and 0Æ1% (n ¼ 6).
In order to analyse this rare cell population, 1 · 106 events
were acquired and a storage gate was set for CD34+CD38)
events (see Materials and methods). Isotype controls and
stringent washing procedures were applied to guarantee the
specificity of the analysis. The gating strategies are displayed in
Fig 1A. Histogram analysis showed that the CD34+CD38) cell
population was completely negative (n ¼ 5; UPNs 01–05) or
had only a very low (n ¼ 1; UPN 06) expression of NG2
(Fig 1A and B).
In ALL/t(4;11), primitive CD34+CD19) cells have been
shown to be part of the leukaemic cell clone (Quijano et al,
1997; Hotfilder et al, 2005). CD34+CD19) cells in diagnostic
samples are rare and in our study comprised only 0Æ25–0Æ6% of
all cells (n ¼ 3). Rare event analysis of this population was
performed as described above. The gating strategies are
displayed in Fig 2A. Similar to what has been found in
previous studies (Baersch et al, 1999), the CD19) population
was heterogeneous. By the use of CD117 expression, a
CD34+CD117+ population that was ‘truly’ negative for CD19
expression (log-normal antigen distribution) could be separ-
ated from a CD34+CD117) population. The latter looked like
the truncated low end of the CD19+ leukaemic bulk popula-
tion. An overlap of populations is a significant problem in the
analysis of rare populations against the background of a
dominant population. In order to avoid this problem,
CD34+CD19)CD117) cells were excluded from the analysis.
Similar to the AML samples, in all three ALL samples analysed,
the most immature CD34+CD19)CD117+ cells did not express
NG2 (Fig 2A and B).
In order to investigate whether NG2 expression is dependent
on differentiation, NG2 expression was correlated with mye-
loid and lymphoid differentiation antigens.
Correlation between NG2 expression and myeloid or
lymphoid differentiation antigens
Because of the stringent gating for CD34+CD38) events, in
four of the six AML samples no CD34+CD33+-positive cells
Lack of NG2 expression on leukaemic stem cells
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Fig 1. (A) Flow cytometric analysis of the neuron-glial antigen 2 (NG2) expression on CD34+CD38) acute myeloid leukaemia (AML) cells in unique
patient number (UPN) 02. Upper left quadrant: the bulk leukaemic population is NG2-positive. Upper right and middle left quadrant: definition of
the rare event gate. Middle right quadrant: forward and side scatter profile of the population. Histograms underline the lack of CD38 and the lack of
NG2 of the gated events (R1). (B) Flow cytometric analysis of the NG2 expression on CD34
+CD38) AML cells in UPN 01–06.
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could be detected inside the storage gate. However, in two
patients a correlation of expression of CD33 with NG2 could
be shown by flow cytometry (Fig 3), which indicated that NG2
was upregulated in AML/abn(11q23) with increasing myeloid
differentiation.
As previously published, 12 ALL/t(4;11) samples were
analysed by FISH, and the immature CD34+CD19) population
was revealed to carry the translocation in 32Æ0–92Æ8% of the
cells (Hotfilder et al, 2005). In six of these 12 ALL samples,
spare RNA was available from sorted CD34+CD19+ and
Fig 2. (A) Flow cytometric analysis of the neuron-glial antigen 2 (NG2) expression on CD34+CD19)CD117+ acute lymphoblastic leukaemia (ALL)
cells in unique patient numbers (UPN) 1. Upper left quadrant: the bulk leukaemic population is NG2-positive. Upper right and second row left
quadrant: definition of the rare event gate. Second row right quadrant: Within the rare event analysis gate (R1) the distinct CD117
+ population is
marked black and was analysed more closely for antibody expression. Whereas the black CD19) cells present the log-normal autofluorescence profile
(R1 + R3), grey events of the same population are only the truncated lower end of the overlap of a log-normal CD19
+ cell population (R1+R2), thus
presenting false negative CD19) cells. (B) Flow cytometric analysis of the NG2 expression on CD34+CD19) CD117+ ALL cells in UPN 1, 2 and 10.
Lack of NG2 expression on leukaemic stem cells
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CD34+CD19) cells for RT-PCR analysis of NG2 expression.
NG2 mRNA could be amplified in the CD34+CD19+ com-
partment of all six patients. Compared with the CD34+CD19+
population, the level of amplification products in
CD34+CD19) cells was always lower (Fig 4). Semiquantitative
RT-PCR revealed a mean 2Æ7 (range: 1Æ5–4Æ454)-fold increase
of NG2 expression in CD34+CD19+ cells compared with
CD34+CD19) cells, underlining the higher expression of NG2
in more mature cells (Table I).
Discussion
Neuron-glial antigen 2 expression has been shown to correlate
with the presence of MLL rearrangement in leukaemic
patients (Hilden et al, 1997; Wuchter et al, 2000; Borkhardt
et al, 2002; Schwartz et al, 2003). Accordingly, we detected
NG2 expression by flow cytometry in nine of 11 patients
(82%) with AML or ALL and cytogenetic or molecular
evidence of 11q23/MLL rearrangement. Despite the cell
surface expression of NG2 on the leukaemic blasts in all nine
patients, candidate leukaemic stem cells were shown to lack
expression of NG2.
In AML, there is solid evidence that the immature
CD34+CD38) cell compartment harbours the leukaemic stem
cells (Lapidot et al, 1994; Bonnet & Dick, 1997; Blair et al,
1998; Bonnet, 2005). Therefore, our results indicate that
primitive CD34+CD38) leukaemic stem cells in AML/
abn(11q23) do not express NG2. Otherwise, it should have
been possible to identify a NG2+CD34+CD38) subpopulation.
Consistent with this observation, flow cytometric analysis
revealed a correlation between the expression of the myeloid
differentiation marker CD33 and increasing levels of NG2 on
maturating AML blasts.
In ALL/t(4;11) the CD34+CD19) cell compartment is more
heterogeneous. While it has been shown that CD34+CD19)
cells are part of the leukaemic cell clone (Hotfilder et al, 2005),
this population cannot, at this stage, be satisfyingly purified, as
there is always significant overlap from the CD19+ bulk
leukaemic population (Vormoor et al, 1998). Till now there
have been debates about whether MLL/AF4-positive leukaemia
arises in a primitive pluripotent stem cell, which is expected to
express the c-kit receptor CD117 (Blair & Pamphilon, 2003) or
in an immature but already lymphoid restricted progenitor/
stem cell that would be expected to be CD117) (Hotfilder et al,
2005). Due to the rarity of the CD34+CD19)CD117+ cell
population, we have been unable to purify these cells for FISH
analysis. This study revealed that the CD34+CD19)CD117+ cell
population lacks expression of NG2, but it could not
determine whether the CD34+CD19)CD117+ cells represent
a normal haematopoietic stem cell population or a NG2-
negative leukaemic stem cell population.
However, in the qualitative RT-PCR, CD34+CD19+ cells
showed, similar to AML, higher concentrations of NG2 RNA
than CD34+CD19) cells. This was confirmed by semiquanti-
tative RT-PCR (Table I) and may indicate that, like in AML,
NG2 is upregulated with lymphoid differentiation within the
ALL cell clone. Yet, low levels of NG2 in ALL stem cells cannot
be totally excluded at this point.
In conclusion, NG2 appears to be upregulated with
increasing myeloid and probably also lymphoid differentiation
within the malignant cell clone of acute leukaemic patients
with MLL rearrangement. This indicates, in contrast to
previous assumptions, that NG2 does not play a key role in
leukaemogenesis ofMLL-rearranged leukaemic patients, as it is
not expressed within the leukaemic stem cell compartment. It
has rather to be considered as an aberrant expression
associated with the MLL fusion oncogenes and probably lacks
any biological function.
These data greatly influence the clinical relevance of NG2
expression. As NG2 is not expressed on primitive cells, it
cannot be utilised as a therapeutic target against leukaemic
stem cells. Moreover, its role in MRD monitoring is limited, as
its expression does not allow a detection of primitive
clonogenic leukaemic stem cells that possess a relapse-
initiating capability.
In conclusion, our results indicate that NG2 expression is a
valuable marker for the diagnosis of acute leukaemia, with
MLL rearrangement, but not a marker of the most relevant
leukaemic stem cells. Other proteins should be tested for their
capacity of detecting the leukaemia-maintaining cell.
Fig 3. Correlation of the myeloid differentiation marker CD33 and the
expression of neuron-glial antigen 2 in acute myeloid leukaemia
unique patient numbers 01 and 06.
J. Neudenberger et al
342 ª 2006 Blackwell Publishing Ltd, British Journal of Haematology, 133, 337–344
A B
Fig 4. Reverse-transcriptase polymerase chain reaction (PCR) analysis of neuron-glial antigen 2 (NG2) mRNA levels in sorted CD34+CD19) (+/))
and CD34+CD19+ (+/+) cell populations in six acute lymphoblastic leukaemia patients. (A) Agarose gel electrophoresis of the qualitative, first-step
PCR for NG2. Arrows indicate the expected and obtained 345-bp PCR product. (B) Crossing point analysis curves of the semiquantitative, second-
step PCR for NG2. Crossing point analysis curves obtained by HeLa dilutions are not shown.
Table I. Relative increase of the neuron-glial antigen 2 mRNA concentration within the CD34+CD19+ cells compared with the CD34+CD19) cells in
six acute lymphoblastic leukaemia patients.
Unique
patient
no. CD34+CD19)CP CD34+CD19)[RNA] CD34+CD19+CP CD34+CD19+[RNA]
[RNA]CD34
+CD19+CD19+/
[RNA]CD34
+CD19)CD19)
1 9Æ665 0Æ383 8Æ506 0Æ575 1Æ500
2 9Æ268 0Æ441 6Æ829 1Æ034 2Æ348
3 10Æ160 0Æ322 8Æ543 0Æ568 1Æ761
4 9Æ615 0Æ390 5Æ410 1Æ700 4Æ357
5 15Æ770 0Æ045 14Æ340 0Æ075 1Æ650
9 12Æ360 0Æ149 8Æ092 0Æ665 4Æ454
Mean: 2Æ678
A semilogarithmic regression curve equation ([RNA] ¼ e2Æ424)0Æ35CP), generated by semiquantitative reverse-transcriptase polymerase chain reaction
(RT-PCR) analysis with dilutions of HeLa cell RNA, was used to calculate the relative amount of NG2 mRNA in sorted CD34+CD19) and
CD34+CD19+ cell populations. The ratio [RNA]CD34
+CD19+CD19+ to [RNA]CD34
+CD19)CD19) indicates the relative increase in NG2 mRNA con-
centration (CP, crossing points obtained by semiquantitative RT-PCR; [RNA], relative NG2 mRNA concentration).
Lack of NG2 expression on leukaemic stem cells
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